Collegium Pharmaceutical ... (COLL)
NASDAQ: COLL
· Real-Time Price · USD
29.82
-0.41 (-1.36%)
At close: May 19, 2025, 3:59 PM
29.83
0.03%
After-hours: May 19, 2025, 04:30 PM EDT
Collegium Pharmaceutical Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Belbuca Revenue | 211.27M | 182.09M | 126.46M | 70.94M |
| Belbuca Revenue Growth | +16.02% | +43.99% | +78.27% | n/a |
| Nucynta ER Revenue | 75.77M | 82.65M | 72.42M | 102.22M |
| Nucynta ER Revenue Growth | -8.33% | +14.13% | -29.16% | n/a |
| Nucynta IR Revenue | 100.74M | 108.15M | 112.06M | 103.71M |
| Nucynta IR Revenue Growth | -6.85% | -3.49% | +8.05% | n/a |
| Symproic Revenue | 15.1M | 16.5M | 12.27M | n/a |
| Symproic Revenue Growth | -8.43% | +34.47% | n/a | n/a |
| Xtampza ER Revenue | 191.33M | 177.37M | 138.8M | n/a |
| Xtampza ER Revenue Growth | +7.87% | +27.79% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 76.42M | 63.09M | 61.95M | 43.34M | 41.98M | 32.94M | 35.3M | 38.19M | 52.77M | 38.03M | 38.37M | 41.25M | 54.53M | 26.6M | 30.51M | 30.37M | 31.48M | 26.82M | 26.43M | 29.32M | 31.26M | 25.09M | 30.07M | 28.93M | 32.35M | 30.45M | 33.45M | 31.28M | 31.58M | 25.09M | 22.76M | 22.06M | 22.85M | 25.37M | 23.57M | 20.17M | 11.53M | 7.91M | 5.91M | 2.93M | 2.19M |
| Selling, General, and Administrative Revenue Growth | +21.13% | +1.83% | +42.97% | +3.22% | +27.44% | -6.67% | -7.58% | -27.63% | +38.76% | -0.89% | -6.99% | -24.34% | +104.98% | -12.82% | +0.48% | -3.52% | +17.34% | +1.51% | -9.88% | -6.20% | +24.59% | -16.57% | +3.93% | -10.56% | +6.24% | -8.96% | +6.93% | -0.96% | +25.88% | +10.24% | +3.15% | -3.44% | -9.93% | +7.64% | +16.82% | +75.04% | +45.79% | +33.82% | +101.33% | +34.28% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.98M | n/a | n/a | 3.98M | 1.61M | 1.45M | 3.46M | 2.93M | 2.47M | 2.14M | 2.49M | 2.67M | 2.4M | 2.49M | 2.46M | 2.99M | 2.25M | 1.91M | 2.24M | 2.27M | 2.19M | 2.07M | 2.18M | 2.13M | 3.33M | 3.25M | 4.3M | 4.06M | 1.53M | 3.36M | 1.64M | 1.45M |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | -100.00% | +147.55% | +10.97% | -58.12% | +18.16% | +18.53% | +15.46% | -14.12% | -6.49% | +11.18% | -3.73% | +1.30% | -17.81% | +33.04% | +17.93% | -14.75% | -1.37% | +3.37% | +6.04% | -5.05% | +2.30% | -36.06% | +2.37% | -24.34% | +5.88% | +165.32% | -54.41% | +104.63% | +13.56% | n/a |